Transparency

How we score evidence.

Every item in Ideas and Learn carries an evidence badge. Here's exactly what each badge means, what we weigh, and how often we revisit them.

The evidence badges

Strong Evidence

Multiple high-quality RCTs, meta-analyses, or established clinical guidelines (NAMS / Menopause Society, ACOG, IMS) point the same way in menopausal populations.

Strong Evidence (RCT)

A high-quality randomized controlled trial in peri- or postmenopausal women supports the claim. Direction of effect is clear.

Strong Evidence (Small Study)

Well-designed RCT with a smaller sample. The effect is likely real, but confidence intervals are wider and replication is still catching up.

Expert Consensus

Clinical guideline bodies and menopause specialists broadly agree — often where a large RCT isn't feasible or ethical.

Emerging Evidence

Early RCTs, or strong mechanistic and observational signal. Promising and plausible, but dose, duration, and replication are still being worked out.

Mixed / Contested Evidence

Studies disagree, or the effect depends heavily on population, timing, or dose. We surface it so you can weigh it with your clinician.

Study hierarchy

When studies disagree, higher-tier evidence wins. We name the study type behind each item.

  1. 01Systematic review / meta-analysis of RCTs in human menopausal populations
  2. 02Randomized controlled trial (RCT) — peri- or postmenopausal cohort
  3. 03Large prospective cohort study (e.g. SWAN, WHI re-analyses)
  4. 04Smaller RCTs or cohort studies in adjacent populations
  5. 05Mechanistic, observational, or animal studies (background only)

What we also weigh

  • • Population match. A study in postmenopausal women carries more weight for a postmenopause claim than one in younger adults.
  • • Effect size and duration. A small effect over 6 months is reported differently than a large effect sustained at 2 years.
  • • Replication. One striking trial is reported as preliminary; three pointing the same way is not.
  • • Conflicts of interest. Industry-funded trials are flagged when relevant.
  • • Clinical guidelines. We cross-check against NAMS / Menopause Society, ACOG, and IMS position statements.

Evidence isn't certainty. Even "Strong Evidence" describes averages, not guarantees. Your history and goals belong in the conversation with your clinician.